Insulet's stock surged 9.57% during intraday trading on Wednesday, following the release of its fourth-quarter financial results that significantly exceeded analyst expectations.

The medical device maker reported quarterly adjusted earnings per share of $1.55, beating the consensus estimate of $1.45, while revenue came in at $783.8 million, surpassing the expected $768.7 million. The strong performance was primarily driven by robust demand for its Omnipod wearable insulin pumps, with total Omnipod revenue rising 33.5% year-over-year.

Insulet also provided optimistic guidance, forecasting first-quarter revenue growth of 25% to 27% and full-year 2026 revenue growth of 20% to 22% in constant currency, with adjusted earnings per share expected to climb more than 25%. Additionally, the company announced a $350 million increase to its share repurchase authorization and plans to allocate approximately $300 million toward buybacks in the first quarter of 2026, which analysts view as a bullish signal supporting investor confidence.